{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:45:29Z","timestamp":1790635529781,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Biol Lett"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>DNA topoisomerase II\u0251 (TOP2A) is crucial for maintaining genomic stability and is an important target for genotoxic chemotherapeutic drugs. STIP1 homology and U-box-containing protein 1 (STUB1) is a U-box containing E3 ubiquitin ligase that participates in the degradation of specific oncogenic proteins. This research examined the potential regulatory function of STUB1 in relation to TOP2A, and explored its functional implications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To identify interactions between STUB1 and TOP2A, coimmunoprecipitation, Glutathione S-transferases (GST) pull-down, and immunofluorescence assays were performed. Cycloheximide (CHX) pulse-chase assay, in vivo and in vitro ubiquitination, quantitative RT-PCR, chromatin immunoprecipitation (CHIP), and luciferase assays were performed to determine how STUB1 interacts with TOP2A. In addition, TOP2A catalytic activity, colony formation, WST-1, and flow cytometry assays were performed and a xenograft model was further developed to explore whether STUB1 could downregulate the catalytic activity of TOP2A, reduce the growth of breast cancer, and increase its sensitivity to doxorubicin. Moreover, immunohistochemical staining was conducted to assess STUB1 and TOP2A expression levels, as well as their predictive roles in the efficacy of neoadjuvant chemotherapy in individuals diagnosed with breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>STUB1 enhanced TOP2A translocation to the cytoplasm, downregulating its expression through increased ubiquitination and degradation. Forkhead box M1 (FOXM1), another substrate of STUB1, served as a transcription factor for TOP2A, playing a role in STUB1-mediated downregulation of TOP2A at the transcriptional level. STUB1 inhibited TOP2A\u2019s activity, reduced cancer cell proliferation, increased doxorubicin-induced apoptosis, and promoted cell cycle arrest. In a breast cancer xenograft model, STUB1 suppressed tumor growth and improved doxorubicin sensitivity. A positive correlation between FOXM1 and TOP2A expression was found in patients with breast cancer undergoing EC-T chemotherapy, both negatively correlated with STUB1, whose higher expression levels were linked to increased pathologic complete response (pCR) rates. STUB1 was evaluated as an independent predictor of pCR through univariate and multivariate analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study proposes a novel function of STUB1 in the downregulation of TOP2A, which directly enhances sensitivity to chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s11658-026-00902-2","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:03:51Z","timestamp":1773871431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["STUB1 downregulates TOP2A through a dual mechanism of ubiquitination and FOXM1-mediated transcription repression, suppressing breast cancer growth and enhancing sensitivity to chemotherapy"],"prefix":"10.1186","volume":"31","author":[{"given":"Baohui","family":"Yue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoling","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"902_CR1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1146\/annurev.biochem.70.1.369","volume":"70","author":"JJ Champoux","year":"2001","unstructured":"Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem. 2001;70:369\u2013413.","journal-title":"Annu Rev Biochem"},{"issue":"1-2","key":"902_CR2","first-page":"83","volume":"623","author":"AK McClendon","year":"2007","unstructured":"McClendon AK, Osheroff N. DNA topoisomerase II, genotoxicity, and cancer. Mutat Res. 2007;623(1\u20132):83\u201397.","journal-title":"Mutat Res"},{"issue":"5","key":"902_CR3","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/modpathol.3880094","volume":"13","author":"PL Depowski","year":"2000","unstructured":"Depowski PL, Rosenthal SI, Brien TP, Stylos S, Johnson RL, Ross JS. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables. Mod Pathol. 2000;13(5):542\u20137.","journal-title":"Mod Pathol"},{"issue":"31","key":"902_CR4","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1038\/onc.2014.332","volume":"34","author":"T Chen","year":"2015","unstructured":"Chen T, Sun Y, Ji P, Kopetz S, Zhang W. Topoisomerase IIalpha in chromosome instability and personalized cancer therapy. Oncogene. 2015;34(31):4019\u201331.","journal-title":"Oncogene"},{"issue":"2","key":"902_CR5","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/ncb1217","volume":"7","author":"J Laoukili","year":"2005","unstructured":"Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A, et\u00a0al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol. 2005;7(2):126\u201336.","journal-title":"Nat Cell Biol"},{"issue":"49","key":"902_CR6","doi-asserted-by":"publisher","first-page":"19330","DOI":"10.1073\/pnas.0806748105","volume":"105","author":"TV Kalin","year":"2008","unstructured":"Kalin TV, Wang IC, Meliton L, Zhang Y, Wert SE, Ren X, et\u00a0al. Forkhead Box m1 transcription factor is required for perinatal lung function. Proc Natl Acad Sci U S A. 2008;105(49):19330\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"902_CR7","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s43587-022-00209-9","volume":"2","author":"R Ribeiro","year":"2022","unstructured":"Ribeiro R, Macedo JC, Costa M, Ustiyan V, Shindyapina AV, Tyshkovskiy A, et\u00a0al. In vivo cyclic induction of the FOXM1 transcription factor delays natural and progeroid aging phenotypes and extends healthspan. Nat Aging. 2022;2(5):397\u2013411.","journal-title":"Nat Aging"},{"key":"902_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2023.03.007","volume":"92","author":"MA Khan","year":"2023","unstructured":"Khan MA, Khan P, Ahmad A, Fatima M, Nasser MW. FOXM1: a small fox that makes more tracks for cancer progression and metastasis. Semin Cancer Biol. 2023;92:1\u201315.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"902_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1158\/1541-7786.MCR-09-0432","volume":"8","author":"JM Kwok","year":"2010","unstructured":"Kwok JM, Peck B, Monteiro LJ, Schwenen HD, Millour J, Coombes RC, et\u00a0al. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res. 2010;8(1):24\u201334.","journal-title":"Mol Cancer Res"},{"issue":"14","key":"902_CR10","doi-asserted-by":"publisher","first-page":"4696","DOI":"10.1074\/jbc.RA119.011280","volume":"295","author":"K Ullah","year":"2020","unstructured":"Ullah K, Chen S, Lu J, Wang X, Liu Q, Zhang Y, et\u00a0al. The E3 ubiquitin ligase STUB1 attenuates cell senescence by promoting the ubiquitination and degradation of the core circadian regulator BMAL1. J Biol Chem. 2020;295(14):4696\u2013708.","journal-title":"J Biol Chem"},{"issue":"1","key":"902_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1097-2765(02)00583-X","volume":"10","author":"Y Imai","year":"2002","unstructured":"Imai Y, Soda M, Hatakeyama S, Akagi T, Hashikawa T, Nakayama KI, et\u00a0al. CHIP is associated with Parkin, a gene responsible for familial Parkinson\u2019s disease, and enhances its ubiquitin ligase activity. Mol Cell. 2002;10(1):55\u201367.","journal-title":"Mol Cell"},{"issue":"3","key":"902_CR12","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1172\/JCI29715","volume":"117","author":"CA Dickey","year":"2007","unstructured":"Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, et\u00a0al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest. 2007;117(3):648\u201358.","journal-title":"J Clin Invest"},{"issue":"24","key":"902_CR13","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1038\/sj.onc.1211010","volume":"27","author":"P Muller","year":"2008","unstructured":"Muller P, Hrstka R, Coomber D, Lane DP, Vojtesek B. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene. 2008;27(24):3371\u201383.","journal-title":"Oncogene"},{"issue":"10","key":"902_CR14","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/onc.2012.144","volume":"32","author":"I Paul","year":"2013","unstructured":"Paul I, Ahmed SF, Bhowmik A, Deb S, Ghosh MK. The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity. Oncogene. 2013;32(10):1284\u201395.","journal-title":"Oncogene"},{"issue":"16","key":"902_CR15","doi-asserted-by":"publisher","first-page":"13829","DOI":"10.1074\/jbc.M209640200","volume":"278","author":"P Zhou","year":"2003","unstructured":"Zhou P, Fernandes N, Dodge IL, Reddi AL, Rao N, Safran H, et\u00a0al. ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem. 2003;278(16):13829\u201337.","journal-title":"J Biol Chem"},{"issue":"1","key":"902_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13058-023-01657-w","volume":"25","author":"M Qi","year":"2023","unstructured":"Qi M, Yi X, Yue B, Huang M, Zhou S, Xiong J. S100A6 inhibits MDM2 to suppress breast cancer growth and enhance sensitivity to chemotherapy. Breast Cancer Res. 2023;25(1):55.","journal-title":"Breast Cancer Res"},{"issue":"29","key":"902_CR17","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1038\/onc.2017.31","volume":"36","author":"Y Shang","year":"2017","unstructured":"Shang Y, He J, Wang Y, Feng Q, Zhang Y, Guo J, et\u00a0al. CHIP\/Stub1 regulates the Warburg effect by promoting degradation of PKM2 in ovarian carcinoma. Oncogene. 2017;36(29):4191\u2013200.","journal-title":"Oncogene"},{"issue":"2","key":"902_CR18","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.immuni.2013.08.006","volume":"39","author":"Z Chen","year":"2013","unstructured":"Chen Z, Barbi J, Bu S, Yang HY, Li Z, Gao Y, et\u00a0al. The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3. Immunity. 2013;39(2):272\u201385.","journal-title":"Immunity"},{"key":"902_CR19","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13023-014-0146-0","volume":"9","author":"K Heimdal","year":"2014","unstructured":"Heimdal K, Sanchez-Guixe M, Aukrust I, Bollerslev J, Bruland O, Jablonski GE, et\u00a0al. STUB1 mutations in autosomal recessive ataxias - evidence for mutation-specific clinical heterogeneity. Orphanet J Rare Dis. 2014;9:146.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"902_CR20","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1038\/s41467-021-23136-6","volume":"12","author":"A Vanden Broeck","year":"2021","unstructured":"Vanden Broeck A, Lotz C, Drillien R, Haas L, Bedez C, Lamour V. Structural basis for allosteric regulation of human Topoisomerase IIalpha. Nat Commun. 2021;12(1):2962.","journal-title":"Nat Commun"},{"issue":"7","key":"902_CR21","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202256458","volume":"24","author":"Y Liu","year":"2023","unstructured":"Liu Y, Yu K, Zhang K, Niu M, Chen Q, Liu Y, et\u00a0al. O-GlcNAcylation promotes topoisomerase IIalpha catalytic activity in breast cancer chemoresistance. EMBO Rep. 2023;24(7):e56458.","journal-title":"EMBO Rep"},{"issue":"6","key":"902_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41419-021-03798-2","volume":"12","author":"C Zhu","year":"2021","unstructured":"Zhu C, Zhang L, Zhao S, Dai W, Xu Y, Zhang Y, et\u00a0al. UPF1 promotes chemoresistance to oxaliplatin through regulation of TOP2A activity and maintenance of stemness in colorectal cancer. Cell Death Dis. 2021;12(6):519.","journal-title":"Cell Death Dis"},{"issue":"1","key":"902_CR23","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12943-023-01846-3","volume":"22","author":"N Khera","year":"2023","unstructured":"Khera N, Rajkumar AS, Abdulkader MAK, Liu Z, Ma H, Waseem A, et\u00a0al. Identification of multidrug chemoresistant genes in head and neck squamous cell carcinoma cells. Mol Cancer. 2023;22(1):146.","journal-title":"Mol Cancer"},{"issue":"1","key":"902_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/leu.2016.270","volume":"31","author":"I Khan","year":"2017","unstructured":"Khan I, Halasi M, Zia MF, Gann P, Gaitonde S, Mahmud N, et\u00a0al. Nuclear FOXM1 drives chemoresistance in AML. Leukemia. 2017;31(1):251\u20135.","journal-title":"Leukemia"},{"issue":"3","key":"902_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.53","volume":"8","author":"Y Hou","year":"2017","unstructured":"Hou Y, Zhu Q, Li Z, Peng Y, Yu X, Yuan B, et\u00a0al. The FOXM1-ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells. Cell Death Dis. 2017;8(3):e2659.","journal-title":"Cell Death Dis"},{"issue":"1","key":"902_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13058-023-01675-8","volume":"25","author":"BS Katzenellenbogen","year":"2023","unstructured":"Katzenellenbogen BS, Guillen VS, Katzenellenbogen JA. Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer. Breast Cancer Res. 2023;25(1):76.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"902_CR27","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.18632\/oncotarget.2957","volume":"6","author":"WT Chiu","year":"2015","unstructured":"Chiu WT, Huang YF, Tsai HY, Chen CC, Chang CH, Huang SC, et\u00a0al. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells. Oncotarget. 2015;6(4):2349\u201365.","journal-title":"Oncotarget"},{"issue":"10","key":"902_CR28","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s43018-020-00116-1","volume":"1","author":"JF Limzerwala","year":"2020","unstructured":"Limzerwala JF, Jeganathan KB, Kloeber JA, Davies BA, Zhang C, Sturmlechner I, et\u00a0al. FoxM1 insufficiency hyperactivates Ect2-RhoA-mDia1 signaling to drive cancer. Nat Cancer. 2020;1(10):1010\u201324.","journal-title":"Nat Cancer"},{"issue":"13","key":"902_CR29","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1158\/0008-5472.CAN-22-0410","volume":"82","author":"D Kopanja","year":"2022","unstructured":"Kopanja D, Chand V, O\u2019Brien E, Mukhopadhyay NK, Zappia MP, Islam A, et\u00a0al. Transcriptional repression by FoxM1 suppresses tumor differentiation and promotes metastasis of breast cancer. Cancer Res. 2022;82(13):2458\u201371.","journal-title":"Cancer Res"},{"issue":"53","key":"902_CR30","doi-asserted-by":"publisher","first-page":"42033","DOI":"10.1074\/jbc.M110.149831","volume":"285","author":"JH Lee","year":"2010","unstructured":"Lee JH, Khadka P, Baek SH, Chung IK. CHIP promotes human telomerase reverse transcriptase degradation and negatively regulates telomerase activity. J Biol Chem. 2010;285(53):42033\u201345.","journal-title":"J Biol Chem"},{"issue":"3","key":"902_CR31","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.cell.2009.12.032","volume":"140","author":"J Yuan","year":"2010","unstructured":"Yuan J, Luo K, Zhang L, Cheville JC, Lou Z. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell. 2010;140(3):384\u201396.","journal-title":"Cell"},{"issue":"6","key":"902_CR32","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1074\/jbc.M114.634386","volume":"290","author":"J Zhang","year":"2015","unstructured":"Zhang J, Yuan C, Wu J, Elsayed Z, Fu Z. Polo-like kinase 1-mediated phosphorylation of Forkhead box protein M1b antagonizes its SUMOylation and facilitates its mitotic function. J Biol Chem. 2015;290(6):3708\u201319.","journal-title":"J Biol Chem"},{"issue":"2","key":"902_CR33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1006\/excr.1999.4587","volume":"251","author":"SE Mirski","year":"1999","unstructured":"Mirski SE, Gerlach JH, Cole SP. Sequence determinants of nuclear localization in the alpha and beta isoforms of human topoisomerase II. Exp Cell Res. 1999;251(2):329\u201339.","journal-title":"Exp Cell Res"},{"issue":"4","key":"902_CR34","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S0006-291X(03)01077-5","volume":"306","author":"SE Mirski","year":"2003","unstructured":"Mirski SE, Bielawski JC, Cole SP. Identification of functional nuclear export sequences in human topoisomerase IIalpha and beta. Biochem Biophys Res Commun. 2003;306(4):905\u201311.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Cellular &amp; Molecular Biology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11658-026-00902-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-026-00902-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-026-00902-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:26:24Z","timestamp":1781641584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s11658-026-00902-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["902"],"URL":"https:\/\/doi.org\/10.1186\/s11658-026-00902-2","relation":{},"ISSN":["1689-1392"],"issn-type":[{"value":"1689-1392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"29 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study of xenograft model was approved by the Institutional Animal Care and Use Committee, Huazhong University of Science and Technology (approval no.: 4183, 01 September, 2024). The Local Ethics Committee confirms that all experiments were conducted in accordance with the ethical principles and guidelines of the International Council for Laboratory Animal Science (ICLAS).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no potential conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}